<DOC>
	<DOCNO>NCT00441012</DOCNO>
	<brief_summary>To determine improvement immune response HBsAg ( hepatitis B virus ) healthy infant use modified process combination Haemophilus Influenzae , type b/Hepatitis B vaccine currently license Haemophilus Influenzae , type b/Hepatitis B vaccine</brief_summary>
	<brief_title>Study Modified Process Hib/Hep B Vaccine Infants ( V121-019 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy 2monthold full term infant bear nonHBs Ag ( hepatitis B virus ) carrier mother Birth mother know carrier hepatitis B virus ( HBsAg+ ) know carrier ever live close contact subject History previous hepatitis B infection ; history vaccination hepatitis B vaccine Recent ( &lt; 72 hour ) history febrile illness ( rectal temperature &gt; =38.1°C/ &gt; =100.5°F ) Known suspect hypersensitivity component RECOMBIVAXHB™ COMVAX™ ( e.g. , aluminum , yeast ) Recent administration ( w/i 3 month prior study start ) hepatitis B immune globulin ( HBIg ) , serum immune globulin , bloodderived product Receipt investigational drug investigational vaccine within 3 month prior study start plan within study period ; Known suspect impairment immunologic function recent use ( within 3 month prior study start ) immunomodulatory medication ( include topical inhaled steroid ) ; Any condition , opinion investigator , might interfere evaluation study objective ; inability comply study schedule and/or inability attend require study visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Days</minimum_age>
	<maximum_age>80 Days</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Haemophilus Influenza , type b Hepatitis B</keyword>
</DOC>